GSK launches $2.5 billion buyback, lifts sales target after stellar fourth quarter
GSK launched a 2 billion pounds ($2.5 billion) share buyback on Wednesday and lifted its long-term sales target to nearly $50 ...
GSK LAWSUIT ALERT: Levi & Korsinsky Notifies GSK plc Investors of a Class Action Lawsuit and Upcoming Deadline
NEW YORK, NY / ACCESS Newswire / February 6, 2025 / If you suffered a loss on your GSK plc (NYSE:GSK) investment and want to learn about a ...
Kepler Capital Sticks to Its Hold Rating for GlaxoSmithKline (GSK)
In a report released on February 5, David Evans from Kepler Capital maintained a Hold rating on GlaxoSmithKline (GSK – Research Report), with ...
Shropshire Star11d
GSK and Oxford researchers to create cancer vaccine to stop disease developing
The University of Oxford and GSK are to work on a vaccine to target cells in the pre-cancerous stage (PA) Pharmaceutical giant GSK and the University of Oxford are creating a new cancer vaccine to ...
FierceBiotech11d
GSK offers up to £50M to conduct cancer vaccine research with the University of Oxford
British pharma giant GSK is heading back to school, pledging up to 50 million pounds sterling (about $62.4 million) to work with the University of Oxford on a cancer vaccine research program.
GSK launches $2.5 billion buyback, lifts sales target after stellar Q4
GSK launched a 2 billion pounds ($2.5 billion) share buyback on Wednesday and lifted its long-term sales target to nearly $50 ...
Fortune29d
GSK, Pfizer RSV shots must warn about rare paralysis risk
Pfizer and GSK vaccines will now be required to carry warnings that they may be tied to an increased risk of a rare neurological side effect. © 2024 Fortune Media IP ...
Fortune24d
British pharma giant GSK to acquire U.S. drug developer IDRx in $1.15 billion deal
© 2024 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and ...
The Independent10d
Cancer vaccine being created by UK scientists could stop disease up to 20 years early
Pharmaceutical giant GSK and the University of Oxford have teamed up to make a vaccine that targets cells at the pre-cancerous stage. The university has world-leading expertise in the study of pre ...
Yahoo Finance25d
GSK Enters Agreement to Acquire IDRx, Inc.
January 13, 2025--(BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) and IDRx, Inc. (IDRx) today announced that they have entered into an agreement under which GSK will acquire IDRx, a Boston-based ...
Benzinga.com23d
GSK Highlights New Approvals, Vaccine Momentum At JPMorgan Healthcare Conference
Depemokimab data reveals 72% reduction in hospitalizations; projected sales hit £4 billion. GSK plc GSK expects strong momentum in the specialty business segment to continue with growth from ...
FierceBiotech25d
JPM25: Strategist GSK acquires IDRx for $1B in hopes of bringing GIST patients new standard of care
In a deal worth up to $1.15 billion, GSK is acquiring precision medicine biotech IDRx and its phase 3-ready gastrointestinal cancer asset. “We really became impressed with what IDRx had achieved ...